Oral Branched-Chain Amino Acid Granules Reduce the Incidence of Hepatocellular Carcinoma and Improve Event-Free Survival in Patients with Liver Cirrhosis
Sosuke Hayaishi(Union Hospital), Kazuomi Ueshima(Kindai University), Hobyung Chung(Kindai University), Masahiro Takita(Kindai University), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Yasunori Minami, Tatsuo Inoue, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Norihisa Yada(Kindai University), Taisuke Ueda(Kindai University), Satoru Hagiwara(Kindai University Hospital)
Cited by 64
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k